BioCam raises €1.16 million to accelerate endoscopy innovation
Investment, Medtech
💎 Polish deep-tech BioCam secures major private round to scale next-generation capsule endoscopy for veterinary and human medicine
BioCam, a Poland-based deep-tech company developing advanced capsule endoscopy for gastrointestinal diagnostics, has raised €1.16 million (approx. 5.1 million PLN) in a new financing round backed entirely by private investors. This marks the largest private round in the company’s history and strengthens its position as one of Central Europe’s fastest-growing medtech innovators. The capital injection will support BioCam’s transition from prototyping to medium-scale production, enabling the company to commercialize its technology first in the veterinary market and prepare regulatory pathways for human medical applications.
At the heart of BioCam’s technology is an endoscopic capsule designed to deliver high-quality imaging without invasive procedures. The latest version represents a significant leap in performance: battery life has been extended from 10–12 hours to up to 30 hours, while the device can capture 150,000 to 300,000 images in a single examination—several times more than earlier prototypes. The system now also includes imaging using a narrow-band illumination spectrum (NBI), a feature intended to enhance diagnostic accuracy by improving visualization of mucosal and vascular structures.
Subscribe to Startup Digest to stay ahead with the latest news, investments, and must-attend events.
BioCam plans to use the round primarily to launch medium-volume production lines, execute initial commercial deployments in veterinary practices, and continue R&D work on its next-generation capsule. The move into the veterinary market is strategic: it allows BioCam to validate its technology in real-world clinical environments while building revenue ahead of regulatory approval for human medicine. If the current trajectory holds, the company estimates that by 2026 it could achieve €455,000–€680,000 in revenue exclusively from veterinary applications, with entry into the human medical market targeted for 2027.
The company has now secured €3.35 million in private capital since 2020 (14.76 million PLN) from a diverse group of early-stage VC funds and angel investors, along with an additional €1.94 million (8.54 million PLN) in non-dilutive European grants. Its investor base includes Level2 Ventures, Smartlink Partners (JRH Group), LT Capital (Movens Capital Group), and Dawid Urban with a network of private backers. These funds have supported BioCam through successive stages of technical development, helping the company advance from a research-driven concept to a commercially viable deep-tech platform.
Looking ahead, BioCam is also considering a pre-IPO round and a potential listing on NewConnect in 2026. However, the final decision will depend on broader capital-market conditions. A successful listing could provide the resources needed to expand production capacity, complete medical certification, and position BioCam as a European leader in non-invasive gastrointestinal diagnostics.
BioCam’s progress underscores the growing momentum of Poland’s medtech ecosystem, where hardware-enabled deep-tech ventures are increasingly attracting private and public funding. As demand rises for minimally invasive diagnostic tools—both in human and veterinary healthcare—BioCam is well positioned to scale its innovation from a regional success story to a globally competitive medical technology platform.
Tags: medtech, investment
